Skip to main content
TipRanks
Go Ultimate75% OFF

CareRx (29C1) Q3 2026 Earnings Report

0 Followers

DE:29C1 Q3 2026 EPS Results

Actual EPS
EUR 0.00
Consensus EPS
EUR 0.02
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
EUR 0.01

DE:29C1 Q3 2026 Revenue Results

Actual Revenue
EUR 60.58M
Expected Revenue
EUR 60.22M
Beat/Miss
Beat by +EUR 355.40K
YoY Revenue Growth
+2.21%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
DE:29C1 Upcoming Earnings

CareRx's next earnings date is estimated for March 10, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-4.76%|
Earnings Call Sentiment|Positive

The call was broadly positive. CareRx delivered revenue growth, increased beds serviced, successfully onboarded approximately 3,000 beds, secured refinancing capacity, maintained conservative leverage and continued returning capital to shareholders. These positives were tempered by lower year-over-year adjusted EBITDA and net income, reduced cash from operations, onboarding-related margin pressure, lumpy timing for additional wins and higher fuel costs. Highlights significantly outweighed the stated challenges.

Company Guidance

For Q4, CareRx said it will see the full value of the benefit of onboarding those 3,000 beds, with an efficiency gain through the full onboard from, call it, October 1 of all 3,000 beds; it also said it should not see any sort of recurring onetime expenses through Q4 related to that onboarding. The company expects to continue onboarding new customers and wins throughout Q4, although some of those expected wins may slide into the new year. Rising gas prices are expected to remain an additional incremental cost through Q4, and the company said it does not think that will change for Q4; there is nothing sort of near term to announce regarding further facility consolidation.

  • Consistent Quarterly Revenue and Adjusted EBITDACareRx generated third-quarter revenue of $95.3 million and adjusted EBITDA of approximately $8.1 million, representing an adjusted EBITDA margin of 8.5%. Net income was approximately $240,000.
  • Growth in Average Beds ServicedAverage beds serviced increased to 93,225 in Q3 2026 from 91,298 in Q3 2025 and 91,719 in Q2 2026. The company said its financial performance reflected contributions from newly onboarded beds, cost savings and efficiency initiatives.
  • Revenue Growth Driven by Bed ExpansionThird-quarter revenue increased 2.2% to $95.3 million from $93.2 million in Q3 2025 and $93.6 million in Q2 2026. The year-over-year increase was driven primarily by the higher number of average beds serviced.
  • Successful Onboarding of National Seniors Home OperatorCareRx substantially onboarded a new national seniors home operator during the quarter, adding approximately 3,000 beds to its network. Management said the company commenced service quickly across communities nationwide and provided a seamless transition and timely service to residents.
  • Platform Capacity and New Business PipelineManagement said the onboarding demonstrated the strength of the CareRx platform and its capacity to take on additional scale. The company continues to see an encouraging pipeline of new business and believes its pharmacy network and team are positioned to support additional growth.
  • New Five-Year Credit AgreementOn August 27, CareRx closed a new credit agreement with National Bank that replaced its previous facility. The agreement includes a $40 million term loan, up to a $20 million revolving operating facility and a $10 million facility dedicated to acquisitions and capital expenditures, with flexibility to increase the revolver and acquisition and capital expenditure facility by up to an aggregate of $20 million. Management expects the agreement to provide greater financial flexibility, dedicated investment capacity and a lower overall cost of capital.
  • Lower Finance CostsExcluding accretion, finance costs declined 15% year over year, reflecting lower borrowing costs.
  • Conservative Leverage and Strong Financial PositionAt September 30, 2026, CareRx had $10.7 million of cash, compared with $9.6 million at the end of Q2 2026. Net debt was $29.6 million, and net debt to adjusted EBITDA remained at 0.9x, in line with Q2. Management described the financial position as very strong and said the company remains positioned to support continued growth while maintaining a conservative leverage profile.
  • Share Repurchases and Dividend DeclarationCareRx renewed its normal course issuer bid, allowing it to repurchase up to 1.75 million common shares through September 16, 2027. It repurchased approximately 207,000 shares in Q3 for approximately $670,000 and approximately 258,000 shares from September 1 through October 31 for approximately $830,000 at an average price of almost $3.21 per share. The Board also declared a quarterly dividend of $0.022 per common share payable January 7, 2027, and the company paid aggregate dividends of $1.4 million on October 8.
  • Network and Office Consolidation InitiativesSubsequent to quarter end, CareRx closed one Western Canada pharmacy location and relocated the beds it serviced to another CareRx fulfillment center to utilize network efficiencies. The company also plans to relocate its corporate support office from downtown Toronto to Richmond Hill in early 2027, adjacent to a fulfillment center, to create greater collaboration between corporate and pharmacy teams.
  • Expected Q4 Benefit from Full Contract OnboardingManagement said Q4 should reflect the full value and efficiency benefit of having all approximately 3,000 new beds onboarded from October 1. Minor one-time onboarding expenses related to the rapid implementation were described as nonrecurring in Q4.
  • Organic Growth and Acquisition OpportunitiesCareRx said it sees meaningful organic growth opportunities through new customer contracts and expansion by existing customers through construction and acquisitions of long-term care and retirement residences. The company also continues to seek accretive acquisitions and intends to use the capacity of its new credit agreement.
  • Expansion of Senior Care Services and InnovationManagement said CareRx aims to use its scale and clinical expertise to extend its impact beyond traditional pharmacy services. The company cited its partnership with Haleon, engagement with long-term care communities and recognition by the Canadian Foundation of Pharmacy as evidence of its innovation and community-focused care.

DE:29C1 Earnings History

DE:29C1 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 10, 20272026 (Q4)0.02-0.24――
Nov 04, 20262026 (Q3)0.020.000.01-100.00% (-0.01)
Jul 29, 20262026 (Q2)0.010.010.010.00% (+0.00)
May 06, 20262026 (Q1)0.030.010―
Mar 04, 20262025 (Q4)0.020.24-0.031025.00% (+0.26)
Nov 03, 20252025 (Q3)0.020.01-0.01300.00% (+0.02)
Jul 30, 20252025 (Q2)0.010.01-0.01150.00% (+0.02)
May 07, 20252025 (Q1)-0.000.00-0.01100.00% (+0.01)
Mar 05, 20252024 (Q4)0.01-0.03-0.0433.33% (+0.01)
Nov 08, 20242024 (Q3)0.01-0.01-0.0150.00% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed